Brown Advisory
CRSP icon

Brown Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Brown Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,622
Closed -$235K – 1408
2025
Q3 		$235K Buy
+3,622
New +$208K ﹤0.01% 1288
2024
Q3 		– Sell
-4,234
Closed -$229K – 1268
2024
Q2 		$229K Buy
4,234
+500
+13% +$28.9K ﹤0.01% 1143
2024
Q1 		$255K Sell
3,734
-21
-0.6% -$1.5K ﹤0.01% 1113
2023
Q4 		$235K Buy
+3,755
New +$208K ﹤0.01% 1123
2022
Q4 		– Sell
-5,057
Closed -$331K – 1213
2022
Q3 		$331K Buy
5,057
+948
+23% +$68.7K ﹤0.01% 944
2022
Q2 		$249K Sell
4,109
-220
-5% -$12.9K ﹤0.01% 990
2022
Q1 		$272K Buy
4,329
+1,282
+42% +$80.5K ﹤0.01% 990
2021
Q4 		$231K Sell
3,047
-30
-1% -$2.62K ﹤0.01% 1132
2021
Q3 		$344K Sell
3,077
-1,042
-25% -$131K ﹤0.01% 909
2021
Q2 		$667K Buy
4,119
+40
+1% +$4.87K ﹤0.01% 793
2021
Q1 		$497K Buy
4,079
+1,057
+35% +$160K ﹤0.01% 848
2020
Q4 		$462K Buy
+3,022
New +$357K ﹤0.01% 797

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown Advisory's CRSP Position: Q4 2025 in Review

Brown Advisory sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,622 shares — an estimated $235K sold.

Brown Advisory first reported a position in CRSP in Q4 2020 and held it in 12 quarters. The position peaked at $667K in Q2 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Brown Advisory reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brown Advisory sold 3,622 CRISPR Therapeutics shares in Q4 2025, an estimated $235K.
  • Brown Advisory first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 12 quarters.
  • Brown Advisory's CRISPR Therapeutics position peaked at $667K in Q2 2021.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Brown Advisory's 13F filing for Q4 2025, filed 13 Feb 2026.